secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0001645113-23-000042
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure annual meeting: directors re-elected, compensation advisory passes with 33% dissent
--------------------------------------------------------------------------------

- All 10 director nominees elected; William Doyle and Timothy Scannell received highest against votes (~2.3M and ~3.4M).
- Ratification of Ernst & Young as auditor for FY2023 approved with 87.4M for, 1.2M against.
- Non-binding advisory vote on executive compensation passed with 52.2M for, 25.3M against (~33% against).
- Approximately 83.5% of shares represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000042/0001645113-23-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000042/nvcr-20230607.htm
  HTML page:      https://secwatch.observer/filing/0001645113-23-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer